Liza Laws's profile photo

Liza Laws

Brighton, United Kingdom

Editor in Chief at Discover Pharma

Trained journalist, currently senior editor for 2 pharma sites, Arsenal observer, Smiths fan, wannabe novelist...and genuine salad fan ♥️

Featured in: Favicon outsourcing-pharma.com Favicon biopharma-reporter.com Favicon linkedin.com Favicon nutraingredients.com Favicon labiotech.eu Favicon newsbreak.com Favicon foodnavigator-usa.com Favicon dairyreporter.com Favicon confectionerynews.com Favicon bakeryandsnacks.com

Articles

  • MindSpire secures £850K to launch SONA wearable and revolutionise stress management with AI-driven vagus nerve tech

    1 week ago | discover-pharma.com | Liza Laws

    Tags: AI healthtech, cognitive performance, Digital Health, health innovation, mental resilience, MindSpire, neurotech, sona, stress management, taVNS, UK biotech, vagus nerve stimulation, wearable techNeurotech start-up MindSpire has raised £850,000 in pre-seed funding to support the launch of its first medical-grade wearable, SONA, designed to help users regulate stress, boost focus and unlock peak cognitive performance.

  • Colorcon and ASHA Cellulose partner to advance barrier membrane technologies for pharma and nutra formulations

    1 week ago | discover-pharma.com | Liza Laws

    Tags: Asha Cellulose, Colorcon, controlled release, Drug Delivery, excipient technology, nutraceuticals, partnership, Pharma Innovation, Pharma Manufacturing, pharmaceutical excipientsColorcon, a specialist in film coatings, excipients, and controlled release technologies, has announced an exclusive partnership with ASHA Cellulose, a manufacturer of ethyl cellulose polymers used across pharmaceutical and dietary supplement applications.

  • High hopes: Ajna turns psychedelics and cannabis into prescription science

    1 week ago | discover-pharma.com | Liza Laws

    Ajna BioSciences is charting a bold course in the pharmaceutical industry by pushing full-spectrum botanical extracts through the FDA’s rigorous drug approval pathway. With its lead candidate DeFloria now entering Phase 2 trials for autism spectrum disorder (ASD), the company is making the case that complex, natural compounds can meet pharmaceutical gold standards.

  • Carta Healthcare raises $18.25M to expand AI-driven clinical data abstraction platform

    1 week ago | discover-pharma.com | Liza Laws

    Tags: AI in Healthcare, Carta Healthcare, clinical data abstraction, Digital Health, healthcare investment, hospital innovation, patient care, real-world data, Series B1 funding, trial matchingCarta Healthcare has secured $18.25 million in Series B1 financing to accelerate the adoption of its AI-powered platform for clinical data abstraction and analytics.

  • Elsevier expands database with ClinicalTrials.gov to support drug and device development

    1 week ago | discover-pharma.com | Liza Laws

    Tags: biomedical data, Clinical Trials, ClinicalTrials.gov, drug safety, Elsevier, Embase, Emtree, medical device development, Regulatory Compliance, systematic reviewsElsevier has announced the addition of over 500,000 clinical trial records to its biomedical literature database, Embase, through the integration of data from ClinicalTrials.gov.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
399
Tweets
973
DMs Open
No
Liza Laws
Liza Laws @Liza77Laws
26 Aug 24

https://t.co/LVBTxc1wqJ

Liza Laws
Liza Laws @Liza77Laws
24 Aug 24

RT @H1co_: H1 and @GRM_Global are on a mission to provide critical #medicalaid in Ukraine. Our CEO talks with @Liza77Laws at @OutsourcPharm…

Liza Laws
Liza Laws @Liza77Laws
21 Aug 24

RT @TheFigen_: The fine line between male and female intelligence. 😂 https://t.co/p4RlfazsVI